1. Home
  2. OLMA vs MTLS Comparison

OLMA vs MTLS Comparison

Compare OLMA & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OLMA
  • MTLS
  • Stock Information
  • Founded
  • OLMA 2006
  • MTLS 1990
  • Country
  • OLMA United States
  • MTLS Belgium
  • Employees
  • OLMA N/A
  • MTLS N/A
  • Industry
  • OLMA Biotechnology: Pharmaceutical Preparations
  • MTLS Computer Software: Prepackaged Software
  • Sector
  • OLMA Health Care
  • MTLS Technology
  • Exchange
  • OLMA Nasdaq
  • MTLS Nasdaq
  • Market Cap
  • OLMA 299.7M
  • MTLS 316.0M
  • IPO Year
  • OLMA 2020
  • MTLS 2014
  • Fundamental
  • Price
  • OLMA $4.65
  • MTLS $5.95
  • Analyst Decision
  • OLMA Strong Buy
  • MTLS
  • Analyst Count
  • OLMA 4
  • MTLS 0
  • Target Price
  • OLMA $24.50
  • MTLS N/A
  • AVG Volume (30 Days)
  • OLMA 825.6K
  • MTLS 75.7K
  • Earning Date
  • OLMA 08-05-2025
  • MTLS 07-24-2025
  • Dividend Yield
  • OLMA N/A
  • MTLS N/A
  • EPS Growth
  • OLMA N/A
  • MTLS 43.31
  • EPS
  • OLMA N/A
  • MTLS 0.17
  • Revenue
  • OLMA N/A
  • MTLS $291,295,936.00
  • Revenue This Year
  • OLMA N/A
  • MTLS $6.42
  • Revenue Next Year
  • OLMA N/A
  • MTLS $8.33
  • P/E Ratio
  • OLMA N/A
  • MTLS $35.21
  • Revenue Growth
  • OLMA N/A
  • MTLS 6.16
  • 52 Week Low
  • OLMA $2.86
  • MTLS $3.93
  • 52 Week High
  • OLMA $16.62
  • MTLS $9.69
  • Technical
  • Relative Strength Index (RSI)
  • OLMA 52.46
  • MTLS 56.27
  • Support Level
  • OLMA $4.38
  • MTLS $5.54
  • Resistance Level
  • OLMA $5.01
  • MTLS $5.84
  • Average True Range (ATR)
  • OLMA 0.30
  • MTLS 0.17
  • MACD
  • OLMA 0.05
  • MTLS 0.01
  • Stochastic Oscillator
  • OLMA 63.64
  • MTLS 79.32

About OLMA Olema Pharmaceuticals Inc.

Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.

About MTLS Materialise NV

Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.

Share on Social Networks: